Gene Expression Profiling Predicts the Development of Oral Cancer

Patients with oral premalignant lesion (OPL) have a high risk of developing oral cancer. Although certain risk factors, such as smoking status and histology, are known, our ability to predict oral cancer risk remains poor. The study objective was to determine the value of gene expression profiling in predicting oral cancer development. Gene expression profile was measured in 86 of 162 OPL patients who were enrolled in a clinical chemoprevention trial that used the incidence of oral cancer development as a prespecified endpoint. The median follow-up time was 6.08 years and 35 of the 86 patients developed oral cancer over the course. Gene expression profiles were associated with oral cancer–free survival and used to develop multivariate predictive models for oral cancer prediction. We developed a 29-transcript predictive model which showed marked improvement in terms of prediction accuracy (with 8% predicting error rate) over the models using previously known clinicopathologic risk factors. On the basis of the gene expression profile data, we also identified 2,182 transcripts significantly associated with oral cancer risk–associated genes (P value < 0.01; univariate Cox proportional hazards model). Functional pathway analysis revealed proteasome machinery, MYC, and ribosomal components as the top gene sets associated with oral cancer risk. In multiple independent data sets, the expression profiles of the genes can differentiate head and neck cancer from normal mucosa. Our results show that gene expression profiles may improve the prediction of oral cancer risk in OPL patients and the significant genes identified may serve as potential targets for oral cancer chemoprevention. Cancer Prev Res; 4(2); 218–29. ©2011 AACR.

[1]  S. Tickoo,et al.  Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice , 2004, Clinical Cancer Research.

[2]  V. Castronovo,et al.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer , 2008, Nature Reviews Cancer.

[3]  S. Dudoit,et al.  Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .

[4]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[5]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression , 2004 .

[6]  Li Mao,et al.  Transcriptomic dissection of tongue squamous cell carcinoma , 2008, BMC Genomics.

[7]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[8]  David Sidransky,et al.  The Oral Cavity as a Molecular Mirror of Lung Carcinogenesis , 2008, Cancer Prevention Research.

[9]  Harald Binder,et al.  Boosting for high-dimensional time-to-event data with competing risks , 2009, Bioinform..

[10]  Simon Talbot,et al.  Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis , 2009, BMC Cancer.

[11]  A. Elkahloun,et al.  A Novel Nuclear Factor-κB Gene Signature Is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status , 2007, Clinical Cancer Research.

[12]  R. Tibshirani,et al.  Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .

[13]  Yan Zeng,et al.  Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2008, Carcinogenesis.

[14]  E. Spisni,et al.  MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. , 2009, Experimental cell research.

[15]  J. Grandis,et al.  Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death , 2009, Molecular Cancer Therapeutics.

[16]  John Quackenbush,et al.  Open source software for the analysis of microarray data. , 2003, BioTechniques.

[17]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[18]  Anne-Mette K. Hein,et al.  Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study , 2007, Clinical Cancer Research.

[19]  P. Sebastiani,et al.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.

[20]  D. Jablons,et al.  Unmet need in lung cancer: can vaccines bridge the gap? , 2008, Clinical lung cancer.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Wersäll,et al.  Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa , 1967, Cancer.

[23]  Edward S. Kim,et al.  Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Patricia Soteropoulos,et al.  Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. , 2004, Cancer genetics and cytogenetics.

[25]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[26]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[27]  K. Coombes,et al.  Microarrays: retracing steps , 2007, Nature Medicine.

[28]  H. Ovaa,et al.  CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. , 2008, Blood.

[29]  Stan Pounds,et al.  Estimating the Occurrence of False Positives and False Negatives in Microarray Studies by Approximating and Partitioning the Empirical Distribution of P-values , 2003, Bioinform..

[30]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[31]  Stuart M. Brown,et al.  Selection and validation of differentially expressed genes in head and neck cancer , 2004, Cellular and Molecular Life Sciences CMLS.

[32]  Shuji Ogino,et al.  DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer , 2009, Clinical Cancer Research.

[33]  A. Seth,et al.  The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. , 2004, European journal of cancer.

[34]  Xi Chen,et al.  An Integrative Pathway-based Clinical-genomic Model for Cancer Survival Prediction. , 2010, Statistics & probability letters.

[35]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[36]  David I. Smith,et al.  Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. , 2008, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[37]  Edward S. Kim,et al.  Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Warnke,et al.  Immune signatures in follicular lymphoma. , 2005, The New England journal of medicine.

[39]  Edward S. Kim,et al.  Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer , 2010, Cancer Prevention Research.

[40]  Edward S. Kim,et al.  Oral Epithelium as a Surrogate Tissue for Assessing Smoking-Induced Molecular Alterations in the Lungs , 2008, Cancer Prevention Research.

[41]  M. Newton,et al.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. , 2007, Cancer research.

[42]  Olivier Poch,et al.  Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis , 2004, Oncogene.

[43]  Giovanni Castagnetti,et al.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. , 2006, Cancer research.

[44]  S. Warnakulasuriya,et al.  Nomenclature and classification of potentially malignant disorders of the oral mucosa. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[45]  Edward S. Kim,et al.  ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia , 2009, Clinical Cancer Research.

[46]  Q. Wei,et al.  Polymorphisms of the DNMT3B gene and risk of squamous cell carcinoma of the head and neck: a case-control study. , 2008, Cancer letters.

[47]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[48]  S. Lippman,et al.  Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.

[49]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. , 2004, Cancer cell.

[50]  Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. , 2007, Cancer research.

[51]  Diane D. Liu,et al.  Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions , 2009, Cancer Prevention Research.

[52]  Q. Dou,et al.  Clinical development of novel proteasome inhibitors for cancer treatment , 2009, Expert opinion on investigational drugs.

[53]  H. Ackermann,et al.  Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines , 2009, Journal of Cancer Research and Clinical Oncology.

[54]  M. Gorsky,et al.  Oral leukoplakia and malignant transformation. A follow‐up study of 257 patients , 1984, Cancer.

[55]  H. Hsu,et al.  Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. , 2007, Lung cancer.

[56]  S. Lippman,et al.  Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.